Lorajmine
Chemical compound
- C01BA12 (WHO)
- (17R,21β)-ajmalan-17,21-diol 17-chloroacetate
OR
(1R,9R,10S,13R,14R,16S,18S)-13-ethyl-8-methyl-14-hydroxy-8,15-diazahexacyclo [14.2.1.01,9.02,7.010,15.012,17]nonadeca-2(7),3,5-triene-18-yl chloroacetate
- 47562-08-3
- 76957773
- 16735878 Y
- F96VX65849
- ChEMBL2111031
- Interactive image
- CCC1C2CC3C4C5(CC(C2C5C(=O)OCCl)N3C1O)C6=CC=CC=C6N4C
InChI
- InChI=1S/C22H27ClN2O3/c1-3-11-12-8-15-19-22(13-6-4-5-7-14(13)24(19)2)9-16(25(15)21(11)27)18(12)20(22)28-17(26)10-23/h4-7,11-12,15-16,18-21,27H,3,8-10H2,1-2H3/t11-,12-,15-,16-,18?,19-,20+,21+,22+/m0/s1 Y
- Key:LAHDERDHXJFFJU-KBFYUGGWSA-N Y
Lorajmine (17-monochloroacetylajmaline) is a drug that is a potent sodium channel blocker (more specifically, a class Ia antiarrhythmic agent) that was used for treating arrhythmia.[1][2][3] It is derived from ajmaline, an alkaloid from the roots of Rauvolfia serpentina, by synthetically adding a chloroacetate residue.
References
- ^ Medical Dictionary Online: Lorajmine
- ^ World Health Organization: ATC/DDD Index
- ^ Sanna G, Meoli P, Bianchini C, Rovelli F (1983). "Antiarrhythmic effectiveness of propafenone compared to lorajmine in ventricular arrhythmias. Controlled clinical trial". Giornale Italiano di Cardiologia. 13 (3): 145–51. PMID 6350090.
- v
- t
- e
class I (Na+ channel blockers) |
| ||||||
---|---|---|---|---|---|---|---|
class III (Phase 3→, K+ channel blockers) | |||||||
class IV (Phase 4→, Ca2+ channel blockers) |
and antagonists
class II (Phase 4→, β blockers) |
|
---|---|
A1 agonist | |
M2 | |
α receptors |
Na+/ K+-ATPase |
---|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e